Literature DB >> 28397114

Neuro-Oncology: Current Concepts and Emerging Therapeutics.

Burt Nabors1, John Laterra2.   

Abstract

Mesh:

Year:  2017        PMID: 28397114      PMCID: PMC5398997          DOI: 10.1007/s13311-017-0529-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  9 in total

1.  Bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; Erik P Sulman; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-05-22       Impact factor: 91.245

2.  Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Authors:  Nicholas F Brown; Thomas Carter; Paul Mulholland
Journal:  CNS Oncol       Date:  2016-10-26

3.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Authors:  Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2009-11-06

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

  9 in total
  1 in total

Review 1.  Therapeutic Options in Neuro-Oncology.

Authors:  Mariana Afonso; Maria Alexandra Brito
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.